Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 46Neoplasms 19Breast Neoplasms 9Head and Neck Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Lung Neoplasms 6Stomach Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Glioblastoma 2Carcinoma, Squamous Cell 2Adenocarcinoma 2Urologic Neoplasms 1Unilateral HER2 Positive Breast Cancer 1Thoracic Neoplasms 1Squamous Non-small Cell Lung Cancer 1Squamous Cell Cancers of the Head and Neck 1Solid Tumors 1Rhabdomyosarcoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Pancreatic Neoplasms 1Oligodendroglioma 1Neuroectodermal Tumors 1Neoplasms, Squamous Cell 1

Interventions

Trastuzumab 1Paclitaxel 1Epirubicin 1Cyclophosphamide 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Unilateral HER2 Positive Breast Cancer × Afatinib × Clear all
NCT01594177 2014-03-13

DAFNE

GBG Forschungs GmbH

Phase 2 Completed
65 enrolled
Breast

Unilateral HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡